Role of liver function tests in detecting methotrexate-induced liver damage in sarcoidosis

Archives of Internal Medicine

Volumn 163, Issue 5, 2003, Pages 615-620

  Baughman, Robert P ^a,c   Koehler, Allison ^a   Bejarano, Pablo A ^a,b   Lower, Elyse E ^a   Weber Jr , Fredrick L ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CORTICOSTEROID; METHOTREXATE;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CONTROLLED STUDY; FEMALE; GROUPS BY AGE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER INJURY; LIVER LEVEL; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE; SARCOIDOSIS; SEX;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CHRONIC DISEASE; FEMALE; HEPATITIS, TOXIC; HUMANS; LIVER FUNCTION TESTS; MALE; METHOTREXATE; MIDDLE AGED; SARCOIDOSIS;

EID: 0037429638     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.5.615     Document Type: Article

References (29)

1. Gedalia A, Molina JF, Ellis GS Jr, Galen W, Moore C, Espinoza LR. Low-dose methotrexate therapy for childhood sarcoidosis. J Pediatr. 1997;130:25-29.
2. Kaye O, Palazzo E, Grossin M, Bourgeois P, Kahn MF, Malaise MG. Low-dose methotrexate: an effective corticosteroid-sparing agent in the musculoskeletal manifestations of sarcoidosis. Br J Rheumatol. 1995;34:642-644.
3. Webster GF, Razsi LK, Sanchez M, Shupack JL. Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. J Am Acad Dermatol. 1991;24:451-454.
4. Lacher MJ. Spontaneous remission or response to methotrexate in sarcoidosis. Ann Intern Med. 1968;69:1247-1248.
5. Veien NK, Brodthagen H. Cutaneous sarcoidosis treated with methotrexate. Br J Dermatol. 1977;97:213-216.
6. Lower EE, Baughman RP, Prolonged use of methotrexate for sarcoidosis. Arch Intern Med. 1995;155:846-851.
7. Lower EE, Broderick JP, Brott TG, Baughman RP. Diagnosis and management of neurologic sarcoidosis. Arch Intern Med. 1997;157:1864-1868.
8. Baughman RP, Lower EE. A clinical approach to the use of methotrexate for sarcoidosis. Thorax. 1999;54:742-746.
9. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis: American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16:149-173.
10. Tolman KG, Clegg DO, Lee RG, Ward JR. Methotrexate and the liver. J Rheumatol. 1985;12(suppl):29-34.
11. van de Kerkhof PCM, Hoefnagels WH, van Haelst JG, Mali JW. Methotrexate maintenance therapy and liver damage in psoriasis. Clin Exp Dermatol. 1985;10:194-200.
12. Kremer JM, Alarcon GS, Lightfoot RW Jr, et al, for the American College of Rheumatology. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum. 1994;37:316-328.
13. Erickson AR, Reddy V, Vogelgesang SA, West SG. Usefulness of the American College of Rheumatology recommendations for liver biopsy in methotrexate-treated rheumatoid arthritis patients. Arthritis Rheum. 1995;38:1115-1119.
14. Roenigk HH Jr, Auerbach R, Mailbach HI, Weinstein GD. Methotrexate guidelines-revised. J Am Acad Dermatol. 1982;6:145-155.
15. Cueller ML, Espinoza LR. Methotrexate use in psoriasis and psoriatic arthritis. Rheum Dis Clin North Am. 1997;23:797-809.
16. Hassan W. Methotrexate and liver toxicity: role of surveillance liver biopsy: conflict between guidelines for rheumatologists and dermatologists. Ann Rheum Dis. 1996;55:273-275.
17. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med. 1991;90:711-716.
18. Maddrey WC, Johns CJ, Boitnott JK, Iber FL. Sarcoidosis and chronic hepatic disease: a clinical and pathologic study of 20 patients. Medicine (Baltimore). 1970; 49:375-395.
19. Devaney K, Goodman ZD, Epstein MS, Zimmerman HJ, Ishak KG. Hepatic sarcoidosis: clinicopathologic features in 100 patients. Am J Surg Pathol. 1993;17:1272-1280.
20. Sherlock S. The liver in sarcoidosis. Semin Respir Med. 1992;13:450-454.
21. Hercules H, Bethlem NM. Value of liver biopsy in sarcoidosis. Arch Pathol Lab Med. 1984;108:831-834.
22. Lower EE, Baughman RP. The use of low dose methotrexate in refractory sarcoidosis. Am J Med Sci. 1990;299:153-157.
23. Baughman RP, Lower EE. Alternatives to corticosteroids in the treatment of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1997;14:121-130.
24. Albera C, Pozzi E, Palmullli P, Guerra S, Nicali R, Ghio P. Low dose steroid plus methotrexate in the treatment of pulmonary sarcoidosis. Eur Respir J. 2000;16 (suppl):370S.
25. Dev S, McCallum RM, Jaffe GJ. Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology. 1999;106:111-118.
26. Fries JF, Ramey DR, Singh G. Suggested guidelines for monitoring liver toxicity in rheumatoid arthritis patients with methotrexate: comment on the article by Kremer et al. Arthritis Rheum. 1994;37:1829-1830.
27. Kremer JM. Liver toxicity does not have to follow methotrexate therapy of patients with rheumatoid arthritis. Am J Gastroenterol. 1997;92:194-196.
28. Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum. 1986;29:822-831.
29. Klatskin G, Yesner R. Hepatic manifestations of sarcoidosis and other granulomatous diseases: a study based on histological examination of tissue obtained by needle biopsy of the liver. Yale J Biol Med. 1950;51:207-248.